Manipulation of Schlemm's effective in treating glaucoma

Article

According to Manfred Tetz and colleagues, Germany, dilation and tensioning of Schlemm's canal may be an effective, non-penetrating surgical method for the treatment of open angle glaucoma (OAG).

According to Manfred Tetz and colleagues, Germany, dilation and tensioning of Schlemm's canal may be an effective, non-penetrating surgical method for the treatment of open angle glaucoma (OAG).

The authors conducted a multicentre, prospective clinical study at three German outpatient surgical centres to determine the safety and efficacy of dilation and tensioning of Schlemm's canal during non-penetrating surgery in glaucoma patients.

A flexible microcannula was introduced into the canal, following surgical exposure, to perform viscodilation of the canal and associated collector channels. The microcannula was used, after 360 degrees of canal cannulation, to insert a 10-0 prolene suture to tension the inner wall of the canal and related trabecular meshwork. Postoperatively, subjects were examined to evaluate the anterior segment and intraocular pressure (IOP), a number of patients were also examined using high resolution ultrasound imaging of the anterior segment angle to evaluate the Schlemm's canal morphology.

To date, the results from 71 subjects have been gathered. Tensioning sutures were observed to distend the inner wall of the canal and trabecular meshwork, whilst also maintaining the canal lumen. Average IOP at six months follow up (n=26) was 14.4 mmHg with an average of 0.2 medications being used. Just four subjects reported adverse events.

Tetz and co-workers noted that viscodilation of the canal restored physiologic drainage and controlled IOP levels. Consequently, they concluded that dilation and tensioning could be an effective non-penetrating surgical method for the treatment of OAG.

Ophthalmology Times Europe reporting from the XXIV Congress of the ESCRS, London, 9-13 September, 2006.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.